Teva gets CRL for Huntington's candidate

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) received an FDA complete response letter for SD-809 deutetrabenazine to treat chorea associated with Huntington's

Read the full 209 word article

User Sign In